Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM - nejm.org

Correspondence from The New England Journal of Medicine — Pembrolizumab in Early Triple-Negative Breast Cancer

To the Editor: In the KEYNOTE-522 trial, Schmid et al.1 reported that the addition of pembrolizumab to neoadjuvant chemotherapy for early triple-negative breast cancer resulted in an increased percen… [+480 chars]

full article...